Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VYNE Therapeutics Q2 EPS $(0.13) Beats $(0.22) Estimate, Sales $69.000K Miss $150.000K Estimate

Author: Benzinga Newsdesk | August 14, 2025 08:05am
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.22) by 41.7 percent. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $69.000 thousand which missed the analyst consensus estimate of $150.000 thousand by 54.00 percent. This is a 65.15 percent decrease over sales of $198.000 thousand the same period last year.

Posted In: VYNE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist